Please upgrade your browser.
Findings from in vitro cell culture studies and a mouse model suggest dual inhibition of mTORC1 and mTORC2 may be a useful treatment for renal cell carcinoma harboring TFE3 gene fusions.
Bionomics has completed enrolment of the 135-patient randomised stage of its DisrupTOR-1 Phase II study of BNC105 in renal cell carcinoma. This puts data read-out on track for January 2014, which is likely to represent a major catalyst for the stock.
Learn about recent advances in kidney cancer research from the world's oldest, largest, and most respected charity dedicated to the eradication of death and suffering from renal cancers.
Bigregistry.org Connects Kidney Cancer Researchers with Patients
Experts believe this could explain why survival rates for women are lower than those for men...
The protective effect of Erythropoietin (EPO) analogue rHuEPO on acute renal injury induced by exhaustive exercise had been reported. The purpose of this study is to probe into the protective effect of EPO on chronic renal injury induced by repeated exhaustive exercise for four weeks.
When Scott Shirley launched Uplifting Athletes in 2007, the nonprofit operated in the basement of his mother’s Enola home.
Just because there is a treatment out there, doesn’t mean that that treatment is good for everyone...
Paracrine communication between different parts of the renal tubule is increasingly recognized as an important determinant of renal function.
Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer...
|Powered by NeonCRM|